Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering...
-
BEDFORD, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced that the Company intends to offer and sell,...
-
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End - - On Track to Initiate Phase 1/2 Trials With In Vivo Gene Editing Candidate for PKU and Gene Therapy...
-
- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - BEDFORD, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq:...
-
BEDFORD, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual...
-
- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLDSymposium™ Support Plans to Initiate a...
-
- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - - Company Plans to Nominate Additional Development Candidate in...
-
- Based on Positive Data, Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase - - $60 Million Equity Investment from Pfizer Inc. - - Unveiled In Vivo Gene Therapy Program...
-
BEDFORD, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million...
-
- Marked Reductions in Phe Observed at Two Doses - - Achieved Goal with Plans to Advance to Randomized, Concurrently Controlled Expansion Phase of Trial - - Webcast / Conference Call Today,...